Kevin V. Morris

11.4k total citations · 5 hit papers
131 papers, 8.7k citations indexed

About

Kevin V. Morris is a scholar working on Molecular Biology, Cancer Research and Virology. According to data from OpenAlex, Kevin V. Morris has authored 131 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Molecular Biology, 52 papers in Cancer Research and 22 papers in Virology. Recurrent topics in Kevin V. Morris's work include RNA modifications and cancer (47 papers), Cancer-related molecular mechanisms research (44 papers) and RNA Research and Splicing (43 papers). Kevin V. Morris is often cited by papers focused on RNA modifications and cancer (47 papers), Cancer-related molecular mechanisms research (44 papers) and RNA Research and Splicing (43 papers). Kevin V. Morris collaborates with scholars based in United States, Australia and South Africa. Kevin V. Morris's co-authors include John S. Mattick, Marc S. Weinberg, Peter G. Hawkins, John J. Rossi, Per Johnsson, David J. Looney, Dan Grandér, Wan Chan, Steven E. Jacobsen and Daniel H. Kim and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Kevin V. Morris

130 papers receiving 8.6k citations

Hit Papers

The rise of regulatory RNA 2004 2026 2011 2018 2014 2004 2013 2023 2024 250 500 750

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Kevin V. Morris 7.3k 4.1k 841 659 539 131 8.7k
Derek M. Dykxhoorn 7.6k 1.0× 2.3k 0.6× 1.4k 1.7× 1.2k 1.9× 1.1k 2.0× 103 9.9k
Carl D. Novina 5.5k 0.8× 1.8k 0.4× 858 1.0× 1.0k 1.6× 279 0.5× 65 7.2k
Sayda M. Elbashir 12.4k 1.7× 2.7k 0.7× 2.1k 2.5× 1.3k 2.0× 219 0.4× 26 14.2k
Ryan A. Flynn 12.9k 1.8× 5.0k 1.2× 1.0k 1.2× 803 1.2× 95 0.2× 69 14.3k
Markus Landthaler 19.1k 2.6× 11.8k 2.9× 605 0.7× 1.4k 2.1× 212 0.4× 103 21.2k
Abdullah Yalçın 11.6k 1.6× 5.4k 1.3× 1.6k 1.9× 1.1k 1.7× 138 0.3× 30 13.5k
Elisa Izaurralde 22.9k 3.1× 5.8k 1.4× 1.4k 1.6× 1.4k 2.2× 473 0.9× 163 25.6k
Jens Harborth 8.7k 1.2× 1.6k 0.4× 1.5k 1.8× 855 1.3× 141 0.3× 24 9.9k
Jack D. Keene 11.4k 1.6× 1.7k 0.4× 1.7k 2.0× 1.4k 2.1× 236 0.4× 148 14.4k
Minchen Chien 3.6k 0.5× 2.3k 0.6× 363 0.4× 529 0.8× 121 0.2× 17 5.3k

Countries citing papers authored by Kevin V. Morris

Since Specialization
Citations

This map shows the geographic impact of Kevin V. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin V. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin V. Morris more than expected).

Fields of papers citing papers by Kevin V. Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin V. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin V. Morris. The network helps show where Kevin V. Morris may publish in the future.

Co-authorship network of co-authors of Kevin V. Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin V. Morris. A scholar is included among the top collaborators of Kevin V. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin V. Morris. Kevin V. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Idris, Adi, Wenqing Gao, Aroon Supramaniam, et al.. (2025). Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation. Drug Delivery and Translational Research. 15(11). 4115–4125. 1 indexed citations
2.
Doerflinger, Marcel, et al.. (2024). Current State of Therapeutics for HTLV-1. Viruses. 16(10). 1616–1616. 4 indexed citations
3.
Idris, Adi, Aroon Supramaniam, Yaman Tayyar, et al.. (2024). An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.. Antiviral Research. 222. 105815–105815. 11 indexed citations
4.
Idris, Adi, Aroon Supramaniam, Roslyn M. Ray, et al.. (2024). Extracellular Vesicles Loaded with Long Antisense RNAs Repress Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Nucleic Acid Therapeutics. 34(3). 101–108. 3 indexed citations
5.
Scott, Tristan, et al.. (2023). Targeted zinc-finger repressors to the oncogenic HBZ gene inhibit adult T-cell leukemia (ATL) proliferation. NAR Cancer. 5(1). zcac046–zcac046. 2 indexed citations
6.
Urak, Ryan, Nicole Grepo, Lior Goldberg, et al.. (2023). Evaluation of the Elements of Short Hairpin RNAs in Developing shRNA-Containing CAR T Cells. Cancers. 15(10). 2848–2848. 2 indexed citations
7.
Troyer, Zach, et al.. (2023). Extracellular vesicles: The next generation in gene therapy delivery. Molecular Therapy. 31(5). 1225–1230. 114 indexed citations breakdown →
8.
Mäkinen, Petri I., Minna U. Kaikkonen, Marc S. Weinberg, et al.. (2022). Nuclear microRNA-466c regulates Vegfa expression in response to hypoxia. PLoS ONE. 17(3). e0265948–e0265948. 12 indexed citations
9.
Youngson, Neil A., et al.. (2022). A role for a novel natural antisense-BDNF in the maintenance of nicotine-seeking. SHILAP Revista de lepidopterología. 2. 100010–100010. 2 indexed citations
10.
Ray, Roslyn M., et al.. (2021). Exosome-mediated stable epigenetic repression of HIV-1. Nature Communications. 12(1). 5541–5541. 61 indexed citations
11.
Scott, Tristan, et al.. (2020). Development of a Facile Approach for Generating Chemically Modified CRISPR/Cas9 RNA. Molecular Therapy — Nucleic Acids. 19. 1176–1185. 6 indexed citations
12.
Baker‐Andresen, Danay, Vikram S. Ratnu, Kevin V. Morris, et al.. (2017). Persistent histone modifications at the BDNF and Cdk‐5 promoters following extinction of nicotine‐seeking in rats. Genes Brain & Behavior. 17(2). 98–106. 14 indexed citations
13.
Vadaie, Nadia & Kevin V. Morris. (2013). Long antisense non-coding RNAs and the epigenetic regulation of gene expression. BioMolecular Concepts. 4(4). 411–415. 39 indexed citations
14.
Morris, Kevin V.. (2012). Non-coding RNAs and epigenetic regulation of gene expression : drivers of natural selection. 19 indexed citations
15.
Morris, Kevin V.. (2009). RNA-Directed Transcriptional Gene Silencing and Activation in Human Cells. Oligonucleotides. 19(4). 299–305. 57 indexed citations
16.
Morris, Kevin V.. (2008). RNA and the regulation of gene expression : a hidden layer of complexity. 34 indexed citations
17.
Jiang, Han, Daniel H. Kim, & Kevin V. Morris. (2007). Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells. Proceedings of the National Academy of Sciences. 104(30). 12422–12427. 221 indexed citations
18.
Barichievy, Samantha, Sheena Saayman, Karin J. von Eije, et al.. (2007). The Inhibitory Efficacy of RNA POL III-Expressed Long Hairpin RNAs Targeted to Untranslated Regions of the HIV-1 5′ Long Terminal Repeat. Oligonucleotides. 17(4). 419–432. 22 indexed citations
19.
Weinberg, Marc S. & Kevin V. Morris. (2006). Are Viral-Encoded MicroRNAs Mediating Latent HIV-1 Infection?. DNA and Cell Biology. 25(4). 223–231. 33 indexed citations
20.
Morris, Kevin V., Wan Chan, Steven E. Jacobsen, & David J. Looney. (2004). Small Interfering RNA-Induced Transcriptional Gene Silencing in Human Cells. Science. 305(5688). 1289–1292. 729 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026